Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Quantitative modeling of tumor dynamics and development of drug resistance in non-small cell lung cancer patients treated with erlotinib.
Yin A, Veerman GDM, van Hasselt JGC, Steendam CMJ, Dubbink HJ, Guchelaar HJ, Friberg LE, Dingemans AC, Mathijssen RHJ, Moes DJAR. Yin A, et al. Among authors: steendam cmj. CPT Pharmacometrics Syst Pharmacol. 2024 Apr;13(4):612-623. doi: 10.1002/psp4.13105. Epub 2024 Feb 20. CPT Pharmacometrics Syst Pharmacol. 2024. PMID: 38375997 Free PMC article.
Influence of Cow's Milk and Esomeprazole on the Absorption of Erlotinib: A Randomized, Crossover Pharmacokinetic Study in Lung Cancer Patients.
Veerman GDM, Hussaarts KGAM, Peric R, Oomen-de Hoop E, Landa KD, van der Leest CH, Broerse SD, Rutten HB, Belderbos HNA, Steendam CMJ, Paats MS, Koolen SLW, Dingemans AC, van Gelder T, van Leeuwen RWF, Aerts JGJV, Mathijssen RHJ. Veerman GDM, et al. Among authors: steendam cmj. Clin Pharmacokinet. 2021 Jan;60(1):69-77. doi: 10.1007/s40262-020-00910-1. Clin Pharmacokinet. 2021. PMID: 32557346 Free PMC article. Clinical Trial.
Plasma Predictive Features in Treating EGFR-Mutated Non-Small Cell Lung Cancer.
Steendam CMJ, Veerman GDM, Pruis MA, Atmodimedjo P, Paats MS, van der Leest C, von der Thüsen JH, Yick DCY, Oomen-de Hoop E, Koolen SLW, Dinjens WNM, van Schaik RHN, Mathijssen RHJ, Aerts JGJV, Dubbink HJ, Dingemans AC. Steendam CMJ, et al. Cancers (Basel). 2020 Oct 29;12(11):3179. doi: 10.3390/cancers12113179. Cancers (Basel). 2020. PMID: 33138052 Free PMC article.
Randomized phase III study of docetaxel versus docetaxel plus intercalated erlotinib in patients with relapsed non-squamous non-small cell lung carcinoma.
Steendam CMJ, Peric R, van Walree NC, Youssef M, Schramel FMNH, Brocken P, van Putten JWG, van der Noort V, Veerman GDM, Koolen SLW, Groen HJM, Dingemans AC, Mathijssen RHJ, Smit EF, Aerts JGJV; NVALT Study Group. Steendam CMJ, et al. Lung Cancer. 2021 Oct;160:44-49. doi: 10.1016/j.lungcan.2021.08.002. Epub 2021 Aug 4. Lung Cancer. 2021. PMID: 34403911 Free article. Clinical Trial.
Plasma Cell-Free DNA Testing of Patients With EGFR Mutant Non-Small-Cell Lung Cancer: Droplet Digital PCR Versus Next-Generation Sequencing Compared With Tissue-Based Results.
Steendam CMJ, Atmodimedjo P, de Jonge E, Paats MS, van der Leest C, Oomen-de Hoop E, Jansen MPHM, Del Re M, von der Thüsen JH, Dinjens WNM, van Schaik RHN, Aerts JGJV, Dubbink HJ; Erasmus MC Cancer Institute. Steendam CMJ, et al. JCO Precis Oncol. 2019 Dec;3:1-9. doi: 10.1200/PO.18.00401. JCO Precis Oncol. 2019. PMID: 35100738
Improving the tolerability of osimertinib by identifying its toxic limit.
Agema BC, Veerman GDM, Steendam CMJ, Lanser DAC, Preijers T, van der Leest C, Koch BCP, Dingemans AC, Mathijssen RHJ, Koolen SLW. Agema BC, et al. Among authors: steendam cmj. Ther Adv Med Oncol. 2022 Jun 3;14:17588359221103212. doi: 10.1177/17588359221103212. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35677320 Free PMC article.
Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer.
Veerman GDM, Boosman RJ, Jebbink M, Oomen-de Hoop E, van der Wekken AJ, Bahce I, Hendriks LEL, Croes S, Steendam CMJ, de Jonge E, Koolen SLW, Steeghs N, van Schaik RHN, Smit EF, Dingemans AC, Huitema ADR, Mathijssen RHJ. Veerman GDM, et al. Among authors: steendam cmj. EClinicalMedicine. 2023 Apr 13;59:101955. doi: 10.1016/j.eclinm.2023.101955. eCollection 2023 May. EClinicalMedicine. 2023. PMID: 37125403 Free PMC article.
Exploring the impact of patient-specific clinical features on osimertinib effectiveness in a real-world cohort of patients with EGFR mutated non-small cell lung cancer.
van Veelen A, Veerman GDM, Verschueren MV, Gulikers JL, Steendam CMJ, Brouns AJWM, Dursun S, Paats MS, Tjan-Heijnen VCG, van der Leest C, Dingemans AC, Mathijssen RHJ, van de Garde EMW, Souverein P, Driessen JHM, Hendriks LEL, van Geel RMJM, Croes S. van Veelen A, et al. Among authors: steendam cmj. Int J Cancer. 2024 Jan 15;154(2):332-342. doi: 10.1002/ijc.34742. Epub 2023 Oct 15. Int J Cancer. 2024. PMID: 37840304
15 results